226 related articles for article (PubMed ID: 24000936)
1. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?
Revelli A; Porcu E; Levi Setti PE; Delle Piane L; Merlo DF; Anserini P
Gynecol Endocrinol; 2013 Nov; 29(11):993-6. PubMed ID: 24000936
[TBL] [Abstract][Full Text] [Related]
2. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Azim AA; Costantini-Ferrando M; Oktay K
J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
[TBL] [Abstract][Full Text] [Related]
3. Response to ovarian stimulation in patients facing gonadotoxic therapy.
Johnson LN; Dillon KE; Sammel MD; Efymow BL; Mainigi MA; Dokras A; Gracia CR
Reprod Biomed Online; 2013 Apr; 26(4):337-44. PubMed ID: 23415997
[TBL] [Abstract][Full Text] [Related]
4. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women.
Checa Vizcaíno MA; Corchado AR; Cuadri ME; Comadran MG; Brassesco M; Carreras R
Reprod Biomed Online; 2012 Jun; 24(6):606-10. PubMed ID: 22503276
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
[TBL] [Abstract][Full Text] [Related]
6. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
Azim AA; Costantini-Ferrando M; Lostritto K; Oktay K
J Clin Endocrinol Metab; 2007 Jun; 92(6):2197-200. PubMed ID: 17356042
[TBL] [Abstract][Full Text] [Related]
7. Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Keskin U; Ercan CM; Yilmaz A; Babacan A; Korkmaz C; Duru NK; Ergun A
J Pak Med Assoc; 2014 Jul; 64(7):830-2. PubMed ID: 25255597
[TBL] [Abstract][Full Text] [Related]
8. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Oktay K; Hourvitz A; Sahin G; Oktem O; Safro B; Cil A; Bang H
J Clin Endocrinol Metab; 2006 Oct; 91(10):3885-90. PubMed ID: 16882752
[TBL] [Abstract][Full Text] [Related]
9. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Fatum M; McVeigh E; Child T
Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
11. High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols.
Ben-Haroush A; Farhi J; Ben-Aharon I; Sapir O; Pinkas H; Fisch B
Isr Med Assoc J; 2011 Dec; 13(12):753-6. PubMed ID: 22332446
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
13. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
Casper RF; Mitwally MF
Clin Obstet Gynecol; 2011 Dec; 54(4):685-95. PubMed ID: 22031258
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Dahhan T; Balkenende EME; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; van Golde RJT; Schipper I; Louwé LA; Cantineau AEP; Smeenk JMJ; de Bruin JP; Reddy N; Kopeika Y; van der Veen F; van Wely M; Linn SC; Goddijn M
Contemp Clin Trials; 2017 Oct; 61():96-100. PubMed ID: 28710053
[TBL] [Abstract][Full Text] [Related]
15. Fertility preservation in women with breast cancer.
Rodriguez-Wallberg KA; Oktay K
Clin Obstet Gynecol; 2010 Dec; 53(4):753-62. PubMed ID: 21048442
[TBL] [Abstract][Full Text] [Related]
16. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
17. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
Oktay K; Buyuk E; Libertella N; Akar M; Rosenwaks Z
J Clin Oncol; 2005 Jul; 23(19):4347-53. PubMed ID: 15824416
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
Dahhan T; Balkenende E; van Wely M; Linn S; Goddijn M
Cochrane Database Syst Rev; 2013 Nov; (11):CD010240. PubMed ID: 24213953
[TBL] [Abstract][Full Text] [Related]
19. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
[TBL] [Abstract][Full Text] [Related]
20. The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation.
Bercaire LMN; Cavagna M; Donadio NF; Rocha AR; Portela R; Alves VR; Santos TBB; Cavagna F; Dzik A; Gebrim LH; Nahas EAP
JBRA Assist Reprod; 2020 Jul; 24(3):257-264. PubMed ID: 32293820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
